$6.99 +0.11 (%) XenoPort Inc - NASDAQ

May. 24, 2016 | 02:50 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Benzinga's M&A Chatter for Thursday January 21, 2016

    Benzinga | Jan. 21, 2016 | 19:30PM EST
  2. Mid-Day Market Update: Crude Oil Surges Over 5%; Paycom Software Shares Tumble

    Benzinga | Sep. 16, 2015 | 13:05PM EST
  3. Mid-Morning Market Update: Markets Gain; Gray Television To Buy Schurz Communications' Television And Radio Stations

    Benzinga | Sep. 15, 2015 | 11:20AM EST
  4. XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis

    Benzinga | Sep. 15, 2015 | 06:31AM EST
  5. XenoPort Reports HORIZANT Included in New Expert Recommendations on Prevention, Treatment of RLS Augmentation

    Benzinga | Jun. 8, 2015 | 08:35AM EST
  6. Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs

    Benzinga | Jan. 22, 2015 | 12:27PM EST
  7. Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

    Benzinga | Jan. 20, 2015 | 13:00PM EST
  8. XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder

    Benzinga | Jan. 11, 2015 | 16:31PM EST
  9. CNBC's Stock Pops & Drops From December 30

    Benzinga | Dec. 31, 2014 | 07:28AM EST
  10. Mid-Day Gainers From December 30: Neuroderm, Neonode And More

    Benzinga | Dec. 30, 2014 | 12:31PM EST
  11. XenoPort Soars 9% Following Comments From RBC's Michael Yee

    Benzinga | Dec. 30, 2014 | 11:38AM EST
  12. Mid-Morning Market Update: Markets Open Lower; Civeo Issues Weak Forecast

    Benzinga | Dec. 30, 2014 | 10:51AM EST
  13. Morning Market Movers

    Benzinga | Dec. 30, 2014 | 09:59AM EST
  14. Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More

    Benzinga | Dec. 30, 2014 | 09:17AM EST
  15. Post-Market Movers for Dec. 29: XNPT, RPRX, ACN Higher; CVEO, JST Lower

    Benzinga | Dec. 29, 2014 | 17:41PM EST
  16. Clinton Group Issues Release Reporting Availability of Proxy Materials for XenoPort Annual Meeting

    Benzinga | Apr. 25, 2014 | 11:50AM EST
  17. XenoPort Files Definitive Proxy Materials and Mails Letter to Stockholders

    Benzinga | Apr. 22, 2014 | 08:33AM EST
  18. US Stock Futures Tumble; All Eyes On P&G, Honeywell Earnings

    Benzinga | Jan. 24, 2014 | 07:04AM EST
  19. XenoPort Prices 12M Share Offering at $6.00/Share

    Benzinga | Jan. 24, 2014 | 05:45AM EST
  20. XenoPort to Offer 10M Shares Common Stock

    Benzinga | Jan. 21, 2014 | 06:05AM EST
  21. XenoPort Reports Feedback from FDA on XP23829

    Benzinga | Jan. 12, 2014 | 17:20PM EST
  22. XenoPort Responds to Clinton Group Call for New CEO

    Benzinga | Oct. 15, 2013 | 22:38PM EST
  23. Jeryl L Hilleman Named Ocera Therapeutics CFO

    Benzinga | Sep. 3, 2013 | 05:49AM EST
  24. XenoPort Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 25, 2012 | 11:03AM EST
  25. UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

    Benzinga | Oct. 12, 2012 | 08:39AM EST
  26. UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on XenoPort

    Benzinga | Oct. 5, 2012 | 04:03AM EST
  27. Socks Hitting 52-Week Highs

    Benzinga | Sep. 20, 2012 | 21:13PM EST
  28. XenoPort Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 09:22AM EST
  29. Social Media Outlook for Friday July 27 (NYT, XNPT, GDOT, STRA)

    Benzinga | Jul. 27, 2012 | 09:02AM EST
  30. XenoPort Announces Pricing of Public Offering of 6.15M Shares at $6.50

    Benzinga | Jul. 26, 2012 | 02:21AM EST
  31. XenoPort Announces Proposed Public Offering of Common Stock

    Benzinga | Jul. 25, 2012 | 10:10AM EST
  32. XenoPort Announces Initiation of a Phase 1 Clinical Trial of XP23829, a Novel Fumarate Analog for the Potential Treatment of Relapsing-Remitting Multiple Sclerosis and Psoriasis

    Benzinga | Jul. 23, 2012 | 10:06AM EST
  33. From Earlier, GSK and XenoPort Receive FDA Approval for Horizant® for Postherpetic Neuralgia

    Benzinga | Jun. 7, 2012 | 01:54AM EST
  34. UPDATE: Credit Suisse Initiates Outperform, $7 PT on XenoPort; Valuation Trumps Fundamental Concerns

    Benzinga | Jun. 7, 2012 | 01:47AM EST
  35. Xenoport Cuts 18 Jobs, Sees Charges of 1.4M, Names Vincent Angotti Operating Chief

    Benzinga | Jun. 4, 2012 | 11:01AM EST
  36. UPDATE: Deutsche Bank Lowers Target on XenoPort to $7

    Benzinga | Feb. 16, 2012 | 01:13AM EST
  37. Wedbush Lowers PT on XenoPort to $15

    Benzinga | Dec. 31, 0000 | 19:00PM EST
Trading Center